This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox 124
From Proteopedia
(Difference between revisions)
| Line 57: | Line 57: | ||
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to | ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to | ||
inhibit PBP2a because additional chemical groups at the | inhibit PBP2a because additional chemical groups at the | ||
| - | <scene name='37/372724/ | + | <scene name='37/372724/Ceftobiprole/7'>R2</scene> |
position of the cephalosporin backbone are able to interact with additional amino acid | position of the cephalosporin backbone are able to interact with additional amino acid | ||
| - | residues in PBP2a; specifically <scene name='37/372724/ | + | residues in PBP2a; specifically <scene name='37/372724/Tyr446_and_met641_label/1'>Tyr446 and Met641</scene>. |
As a result of its <scene name='37/372724/R2_interaction/3'>tighter binding</scene> to PBP2a, ceftobiprole | As a result of its <scene name='37/372724/R2_interaction/3'>tighter binding</scene> to PBP2a, ceftobiprole | ||
is able to more efficiently react with the serine active site residue and therefore inhibit the activity of PBP2a. | is able to more efficiently react with the serine active site residue and therefore inhibit the activity of PBP2a. | ||
Revision as of 16:21, 14 August 2013
| |||||||||||
